One of the most common genetic linkages associated with neuropsychiatric disorders, such as autism spectrum disorder and schizophrenia, occurs at the 16p11.2 locus. Copy number variants (CNVs) of the 16p gene can manifest in opposing head sizes. 16p11.2 deletion carriers tend to have macrocephaly (or brain enlargement), while those with 16p11.2 duplication frequently have microcephaly. Increases in both gray and white matter volume have been observed in brain imaging studies in 16p11.2 deletion carriers with macrocephaly. Here, we use human induced pluripotent stem cells (hiPSCs) derived from controls and subjects with 16p11.2 deletion and 16p11.2 duplication to understand the underlying mechanisms regulating brain overgrowth. To model both gray and white matter, we differentiated patient-derived iPSCs into neural progenitor cells (NPCs) and oligodendrocyte progenitor cells (OPCs). In both NPCs and OPCs, we show that CD47 (a 'don't eat me' signal) is overexpressed in the 16p11.2 deletion carriers contributing to reduced phagocytosis both in vitro and in vivo. Treatment of 16p11.2 deletion NPCs and OPCs with an anti-CD47 antibody to block CD47 restores phagocytosis to control levels. Furthermore, 16p11.2 deletion NPCs and OPCs upregulate cell surface expression of calreticulin (a pro-phagocytic 'eat me' signal) and its binding sites, indicating that these cells should be phagocytosed but fail to be eliminated due to elevations in CD47. While the CD47 pathway is commonly implicated in cancer progression, we document a novel role for CD47 in regulating brain overgrowth in psychiatric disorders and identify new targets for therapeutic intervention.
Introduction
Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder, characterized by deficits in social interaction and communication and frequently associated with restrictive, repetitive behaviors. ASD is the fastest growing developmental disability, affecting 1 in 59 children in the United States. Heterogeneity and access to relevant cell types have made it challenging to understand underlying mechanisms and identify effective therapies for ASD. 16p11.2 copy number variation (CNV) is one of the most common genetic linkages of ASD as well as other intellectual disabilities and developmental delays 1-7 .
A large head size (referred to as macrocephaly) is common in people who have 16p11.2 deletion syndrome. Head circumference is highly correlated with brain size early in development 8 . While macrocephaly refers to having enlarged head circumference (typically greater than the 97th percentile), microcephaly refers to having small head circumferences below the 3 rd percentile 9 . Meta-analyses studies have found that approximately 15-20% of individuals with ASD have macrocephaly 9,10 , with disproportionate enlargement in both gray and white matter volume 11, 12 . Individuals with ASD and macrocephaly have more severe behavioral and cognitive problems--such as lower language ability and slower cognitive development into early childhood--and are less responsive to standard medical and therapeutic interventions, leading to very poor prognoses relative to individuals with ASD and normal head circumferences 13 . Increases in brain size often precede clinical symptoms [12] [13] [14] , suggesting that understanding the underlying mechanisms regulating brain overgrowth could provide a window of opportunity for intervention or mitigation of symptoms. It is important to use human-derived samples to better understand the disorder 15 , because 16p11.2 CNV in mouse models affects a different set and number of genes within the 16p locus and has the opposite phenotype relative to humans-enlarged brains in 16p11.2 duplication and microcephalic brains in the 16p11.2 deletion syndrome 16, 17 .
Here, we focus on a clinically meaningful subtype of individuals with intellectual disability (IQ<70) or ASD associated with brain overgrowth in 16p11.2 deletion carriers. We use patient-derived human induced pluripotent stem cells (hiPSCs) to interrogate the underlying mechanisms contributing to gray and white matter enlargement. Specifically, we differentiate the iPSCs into neural progenitor cells (NPCs) and oligodendrocyte progenitor cells (OPCs) and investigate the hypothesis that brain enlargement in 16p11.2 deletion carriers may be due to improper cellular elimination. Under normal conditions, classical 'eat me' and 'don't eat me' signaling mechanisms associated with phagocytosis maintain cellular homeostasis across diverse tissue types 18, 19 . We investigated whether these signaling mechanisms may be deregulated in conditions associated with brain overgrowth. We show that CD47 (a 'don't eat me' signal) is overexpressed in NPCs and OPCs derived from 16p11.2 deletion carriers leading to reduced phagocytosis by macrophages and microglia. Furthermore, treatment with a CD47 blocking antibody can restore phagocytosis of 16p11.2 deletion NPCs and OPCs to control levels. Importantly, the 16p11.2 deletion NPCs and OPCs have increased cell surface expression of calreticulin (a prophagocytic 'eat me' signal), indicating that these cells should be eliminated but are not due to high levels of CD47 20 . We identify a novel role for CD47 in regulating brain size and highlight the importance of blocking CD47 to promote clearance of unhealthy NPCs and OPCs in 16p11.2 deletion with brain overgrowth.
To our knowledge, this is the first study to uncover a role for CD47 in neurodevelopmental disorders, such as ASD. A recent genome-wide association study (GWAS) has identified CD47 as a significant risk loci for bipolar disorder 21 , providing support that CD47 may play critical roles in brain regulation and function. Consistent with recent work on the role of CD47 in regulating synaptic pruning in brain development 22 and social behavior in mouse models 23 , our study further highlights that the balance between 'eat me' and 'don't eat me' signals may be more broadly playing critical roles during early neurodevelopment.
Results

Upregulation of CD47 in 16p11.2 deletion NPCs suppresses phagocytosis
We obtained human iPSCs from the Simons Foundation Autism Research Initiative (SFARI) from individuals who are carriers of the 16p11.2 CNV with complete clinical and phenotypic data. To better understand and elucidate mechanisms underlying brain overgrowth, we focused our study on 16p11.2 deletion carriers with defined macrocephaly (mean head circumference of 97± 2 percentile; three 16p11.2 del subjects had head circumferences in the 99th percentile, and one 16p11.2 del subject had a head circumference in the 91st percentile) ( Figure 1A , Supplementary Table 1 ). All four of these 16p11.2 del subjects have been diagnosed with intellectual disability (IQ<70) or ASD ( Supplementary Table 1 ) as well as phonological and/or language disorders. Two 16p11.2 deletion carriers with normal head circumferences without macrocephaly ( Supplementary Table 1 ) were also used as comparison to identify whether our findings are specific to 16p11.2 deletion or 16p11.2 deletion with brain overgrowth. 16p11.2 duplication carriers in our study have head circumference percentiles within the normal range of 42.5±30.5 percentile with no diagnosis of macro-or microcephaly ( Figure 1A , Supplementary Table 1 ). iPSCs from control subjects were obtained through the NIH registry with no genetic abnormalities.
To confirm CNV status of the iPSCs, we first assessed mRNA levels of a subset of genes spanning the 16p11.2 locus by quantitative RT-PCR (qRT-PCR). Expression levels of many genes within this locus were significantly upregulated in the 16p11.2 duplication (16p_dup) lines and downregulated in the 16p11.2 deletion (16p_del) lines relative to control iPSCs ( Figure 1B ). Expression of pluripotency markers (Nanog and Oct4) were uniformly expressed and comparable in the 16p11.2 CNV iPSCs and control iPSCs (Supplementary Figure 1A and 1B).
Increases in gray matter volume have been associated with brain enlargement in 16p11.2 deletion carriers with macrocephaly 24, 25 . Increases in neural progenitor cell (NPC) proliferation and neuronal cell size have been associated with brain overgrowth using iPSC models of ASD with macrocephaly or 16p11.2 CNV iPSCs, respectively 26, 27 . Using iPSC modeling in two-and three-dimensional systems, recent work has shown that the critical period during which gene networks become dysregulated in autism with macrocephaly occurs early at the neural stem cell stage prior to further differentiation and maturation into neurons 28 . While sample sizes in these iPSC studies tend to be small (ranging from 3 in Deshpande et al., 2017 to 8 autistic subjects with macrocephaly in Marchetto et al., 2017 and Schafer et al., 2019) , these studies nonetheless highlight that iPSCs can be used to model brain overgrowth in autism and gain insight on underlying mechanisms. To begin to model gray matter using human iPSCs, we differentiated the iPSCs into NPCs using an established NPC differentiation protocol that gives rise to cortical neurons 29, 30 . Following 12 days of directed differentiation ( Figure 1C ), NPCs express Pax6 mRNA at comparable and high levels of >1000-fold relative to undifferentiated iPSCs ( Figure 1D ). Expression of Pax6 at the protein level was also comparable across conditions ( Figure 1E ) and was coexpressed with nestin ( Supplementary Figure 2A) , an intermediate filament protein expressed in neural stem and progenitor cells 31 .
CD47, commonly known as a 'don't eat me' signal, protects normal cells from getting cleared 19 , but can become overexpressed in many types of cancer cells, preventing tumorigenic cells from getting engulfed or phagocytosed [32] [33] [34] . Recent work has shown that CD47 also plays a role in synaptic pruning 22 , suggesting that it may play an important regulatory role in neurodevelopment. We hypothesized that brain enlargement in 16p11.2 deletion carriers may be due to improper cellular elimination as a result of altered CD47 expression. To investigate this possibility, we first assessed mRNA expression levels of CD47 in the differentiated NPCs from 16p11.2 CNV carriers and control subjects. Strikingly, CD47 expression was significantly upregulated in 16p_del carriers relative to control and 16p_dup subjects ( Figure 1F ). Flow cytometry analysis for CD47 protein expression at the cell surface also showed a significant shift and upregulation in the mean fluorescence intensity (MFI) in 16p_del carriers relative to control and 16p_dup subjects ( Figure 1G and 1H). Importantly, CD47 expression of NPCs derived from 16p_del carriers with normal size brains (average head circumference of 50.2±2.2 percentile) was comparable to control and 16p_dup individuals (Supplementary Figure 3A -E), suggesting that the upregulation of CD47 is specific to individuals with macrocephaly in 16p11.2 deletion syndrome.
With the finding of increased CD47 expression in 16p11.2 del NPCs, we hypothesized these cells would escape recognition and phagocytosis. To test the functional significance of our findings, we derived macrophages from control human blood samples and co-cultured them in vitro with differentiated NPCs from 16p11.2 CNV and control subjects. While NPCs derived from control and 16p_dup subjects had similar rates of phagocytosis as assessed by co-labeling with the marker CD45, there was a significant reduction in engulfment of the 16p_del NPCs ( Figure 1I and 1J). Treatment with CD47 blocking antibody can effectively restore phagocytosis of cancer cells that overexpress CD47 without affecting normal cells [35] [36] [37] [38] [39] . To investigate whether blocking CD47 could restore phagocytic activity, we pretreated 16p_del NPCs with a CD47Ab (anti-CD47 antibody clone B6.H12) and assessed the rate of phagocytosis when cocultured with macrophages. Strikingly, blockade of CD47 restored phagocytosis to control levels in the 16p_del NPCs ( Figure 1I and 1J), potentially indicating a novel therapeutic intervention for this psychiatric disorder. Notably, CD47 expression at the mRNA and protein levels as well as phagocytosis rates were similar across groups prior to differentiation at the pluripotent stage (Supplementary Figure  1C -G), emphasizing the role of CD47 in maintaining phagocytic balance during development and highlighting that these findings were specific to the differentiated NPCs.
Upregulation of CD47 in 16p11.2 deletion OPCs suppresses phagocytosis
In addition to increases in gray matter, brain imaging studies have shown increases in white matter volume in 16p11.2 deletion carriers with macrocephaly 11, 24, 25, 40, 41 . While human iPSC-derived oligodendrocytes have been used to model psychiatric disorders, such as schizophrenia 24, 42 , no cellular models investigating white matter overgrowth in 16p11.2 deletion syndrome have yet been developed and investigated. To begin to model white matter using human iPSCs, we differentiated the iPSCs into oligodendrocyte progenitor cells (OPCs) using an established differentiation protocol that enables iPSCderived OPCs to engraft and function in vivo in the mouse brain 43 (Figure 2A ). Following 12 days of directed differentiation, the cells express pre-OPC markers, Olig2 and Nkx2.2 at the protein level 43 ( Figure 2B ). With further differentiation to day 50, mRNA expression of several genes associated with the oligodendrocyte lineage (e.g. Olig1) 43 are upregulated ( Figure 2C ). Following 50 days of differentiation, immunostaining and flow cytometry analyses show that the population of cells also express more mature OPC markers at the protein level, including SRY-box 10 (SOX10) ( Figure 2D ), the cell surface marker O4 ( Figure 2E ), and the chondroitin sulfate proteoglycan NG2 (Supplementary Figure  4) , demonstrating that the majority of the cells are differentiating into the oligodendrocyte lineage 43 . In subsequent analyses, we collectively call the day 50 population as OPCs.
To investigate the role of CD47 in OPCs, we next assessed the mRNA expression level of CD47 following 12 days of directed differentiation, when the cells are still in the early stages of differentiation at a pre-OPC stage 43 . No significant difference in CD47 expression was detectable at this early stage across all 16p CNV and control lines ( Figure 2F , left panel). However, after 50 days of differentiation, there was a significant increase in CD47 expression in the 16p_del OPCs compared with 16p_dup and control OPCs ( Figure 2F , right panel). O4+ OPCs can be isolated through fluorescence activated cell sorting (FACs) using established protocols 44 . In O4+ sorted OPCs, mRNA expression of CD47 was also significantly upregulated, up to 15000-fold in 16_del relative to control and 16p_dup conditions (Supplementary Figure 5A ). Across all conditions, the O4+ OPCs had high mRNA expression levels of genes associated with the oligodendrocyte lineage (Supplementary Figure 5B and 5C), low expression levels of neuronal (Tuj1) and astrocytic (GFAP) genes (Supplementary Figure 5C ), and were of cortical origin as genes associated with the spinal cord had low expression (Supplementary Figure 5D ). Similar to the NPCs, there was a significant shift and upregulation of the MFI of CD47 at the protein level at the cell surface of 16p_del OPCs compared to control and 16p_dup subjects after 50 days of differentiation ( Figure 2G and 2H). This upregulation in CD47 corresponded with suppressed phagocytosis when the OPC populations were co-cultured with macrophages derived from control human blood samples ( Figure 2I ). As in NPCs, treatment with the blocking antibody, CD47Ab (anti-CD47 antibody clone B6.H12), restored phagocytosis rates to control levels in 16p_del OPCs ( Figure 2I and 2J). Similar to the NPCs, CD47 expression of OPCs derived from 16p_del carriers with normal size brains (average head circumference of 50.2±2.2 percentile) was comparable to control and 16p_dup individuals (Supplementary Figure 6A -C), providing further support that the upregulation of CD47 is specific to individuals with macrocephaly in 16p11.2 deletion syndrome.
Overexpression of CD47 leads to suppressed phagocytosis of 16p11.2 deletion NPCs and OPCs in vivo
Thus far, our results show that overexpression of CD47 in the 16p_del NPCs and OPCs is associated with suppressed phagocytosis in vitro. We next investigated whether phagocytosis rates would also be altered and recapitulated in an in vivo setting following intracerebral injections of 16p11.2 CNV-derived NPCs or OPCs. To do so, following in vitro directed differentiation, hiPSC-derived NPCs and OPCs were labeled with CellTrace red fluorescent dye and injected intracerebrally into individual NOD-scid IL2gammanull (NSG) P2 pups ( Figure 3A ). 24h after injection, pups were euthanized and brains were dissociated for flow cytometry analyses of phagocytosis. Within the target cell population identified by CellTrace Far Red, the percentage of cells co-labeled with CD45 and CD11b, markers of activated microglia and infiltrating macrophages, were analyzed to determine phagocytosis rates ( Figure 3A) 45 . Similar to the in vitro experiments, the percentages of engulfed or phagocytosed NPCs ( Figure 3B and 3C) and OPCs ( Figure 3D and 3E) were significantly suppressed in vivo in the 16p_del conditions relative to control and 16p_dup conditions. Strikingly, treatment with an anti-CD47 blocking antibody of 16p_del NPCs and OPCs prior to intracerebral injections restored in vivo phagocytosis rates to control levels ( Figure 3B -E).
Anti-CD47 treatment restores in vivo phagocytosis of 16p11.2 deletion NPCs and OPCs
To assess therapeutic implications, we next evaluated whether intraperitoneal (i.p.) anti-CD47 treatment could restore phagocytosis of 16p11.2_del NPCs and OPCs in vivo, analogous to an approach that has proven to be beneficial in human clinical trials of patients with lymphoma 39 . After intracerebrally injecting CellTrace Far Red-labeled 16p11.2_del NPCs and OPCs into NSG pups, we treated the pups with anti-CD47 (Hu5F9-G4) or human IgG control antibodies intraperitoneally and analyzed phagocytosis by flow cytometry after 24h ( Figure 4A ). Compared to IgG control, treatment with anti-CD47 antibody was associated with a marked increase in phagocytosis, both in 16p_del NPCs ( Figure 4B and 4C) and 16p_del OPCs ( Figure 4D and 4E). Additionally, we used antibodies to ionizing calcium-binding adaptor molecule (Iba1), a microglial and macrophage-specific calcium-binding protein that is involved in membrane ruffling and phagocytosis 46 , to immunolabel and identify phagocytic cells in NSG pup brain tissue sections. Consistent with the flow cytometry analyses, increased Iba1+ cells engulfing target cells marked by the human cytoplasmic marker (STEM121) along with CellTrace Far Red at the injection site were evident in 16p_del brains treated with anti-CD47 antibody relative to control IgG treatment ( Figure 4F ). Taken together, these results indicate that CD47-blockade could act as a therapeutic agent in clearing NPCs and OPCs in the 16p11.2 deletion syndrome.
Upregulation of the pro-phagocytic signal Calreticulin in 16p11.2 deletion NPCs and OPCs
Under normal conditions, cell homeostasis is maintained by the balance of pro-and anti-phagocytic signals. Calreticulin is a dominant pro-phagocytic signal (commonly known as an 'eat me' signal) that is upregulated on the surfaces of cancer cells as well as damaged and aged cells, indicating to the phagocytic system that the cells should be eliminated 47 . However, due to high levels of CD47, which dominates the pro-phagocytic calreticulin signal, these cells fail to be eliminated 20 . Importantly, translocation of calreticulin to the cell surface of target cells determines cell removal 47 . Here, we assessed cell surface levels of calreticulin (CRT) by flow cytometry in the differentiated NPCs and OPCs. NPCs and OPCs derived from 16p_del iPSCs had a significant upregulation of CRT relative to control and 16p_dup subjects ( Figure 5A -B, 5D-E). Furthermore, CRT binds to asialoglycans on the surface of cells, therefore the more potential binding sites, desialated glycans, the more potential calreticulin there is to promote interrogation and clearance by the phagocytic system. The absence of sialic acid on glycans can be determined by using a lectin, Phaseolus Vulgaris Leucoagglutinin (PHA-L) 47 . Staining with PHA-L on NPCs and OPCs derived from control and 16p_CNV iPSCs shows a marked increase in PHA-L binding in 16p_del subjects ( Figure 5C and 5F), indicating increased presence of asialoglycan binding sites for CRT. In individuals with 16p11.2 deletion with normal head circumferences (no macrocephaly), expression of CRT was comparable to control subjects (Supplementary Figure 3F, Supplementary Figure 6D ). Together, this indicates that the NPCs and OPCs in 16p11.2 deletion syndrome with brain enlargement should be eliminated but fail to be due to high expression of CD47. These data further support the importance of anti-CD47 treatment as a means to promote clearance of unhealthy NPCs and OPCs in 16p11.2 deletion syndrome with brain overgrowth.
Discussion
While CD47 has been extensively studied in cancer 20, [32] [33] [34] [35] 38 , this study begins to uncover its implications for neurodevelopmental disorders associated with brain overgrowth. Recent work has shown that CD47 plays a critical role in regulating synaptic pruning during early brain development 22 , providing further support that the same pathways can go awry in neurodevelopmental disorders. While a number of studies are beginning to show changes in NPC proliferation 26, 28 and neuronal size 27 associated with autism with brain enlargement, these studies focused on changes in gray matter and have only investigated molecular and cellular mechanisms in cultures in vitro [26] [27] [28] . We demonstrate that CD47 is upregulated in two distinct cell types (NPCs and OPCs) at particular stages of development in 16p11.2 deletion syndrome, leading to suppressed phagocytosis both in vitro and in vivo. Moreover, we provide evidence that these findings are specific to individuals with macrocephaly and not those with normal head circumferences with 16p11.2 deletion syndrome. We demonstrate that anti-CD47 treatment can act as a therapeutic agent for clearing unhealthy cells in cellular and mouse models, potentially indicating that these forms of therapy could be translated to selected autistic individuals with brain overgrowth early in the disease.
In acute myeloid leukemia (AML), the hematopoietic stem cell precursors of AML out-compete normal hematopoietic stem cells, enabling the leukemia stem cells to expand beyond by countering signaling associated with programmed cell removal, such as calreticulin, with overexpression of CD47 20, [48] [49] [50] . The imbalance between CD47 and calreticulin observed in this study may indicate that specific NPCs and OPCs in the 16p deletion syndrome with brain overgrowth undergo clonal expansion and outcompete normal NPCs and OPCs. Future work should evaluate whether expansion of CD47hi NPC or OPC clones contribute to brain overgrowth in psychiatric and neurodevelopmental disorders, such as autism. Interestingly, a surprising number of genes (e.g. PTEN, CHD8) and cellular pathways involved in cancer have been found to overlap with those implicated in autism [51] [52] [53] [54] . This not only indicates potentially shared mechanisms between autism and cancer, but also that the breadth of therapeutic agents identified for cancer could be beneficial in autism and other neurodevelopmental disorders. Here, we demonstrate the efficacy of anti-CD47 monoclonal antibodies as a potential therapeutic in restoring phagocytosis of 16p11.2 deletion NPCs and OPCs. Within the 16p11.2 locus, approximately 29 genes are affected in 16p11.2 CNV carriers 5 . In future work, it would be interesting to investigate which of these 29 genes directly regulates the CD47 pathway and/or the regulation of asialoglycoproteins (binding sites for calreticulin), which could have important implications for cancer, neurodevelopment, and other conditions associated with CD47 signaling. Similarly, as in some forms of cancer 55 , it would be interesting to investigate whether changes in epigenetics (e.g. H3K27 acetylation) of 16p11.2 deletion NPCs and OPCs influence enhancers and super enhancers to regulate CD47 expression.
We acknowledge that while the sample sizes in this study are small (but comparable to other iPSC studies modeling subtypes of psychiatric disorders) [26] [27] [28] 56 , they would benefit from including more patients with 16p11.2 deletion and/or other disorders with defined macrocephaly. Validating these findings in postmortem brain tissue in 16p11.2 deletion individuals with brain overgrowth would also be valuable, though this resource is limited and constrained by the fact that most brain banks worldwide do not have head circumference or brain volume data tagged with postmortem human brain tissue. Nonetheless, iPSCs are increasingly proving to be a valuable resource in understanding the mechanisms regulating brain development and growth. In recent work, proliferation of NPCs has been shown to be suppressed in human iPSC models of patients with psychiatric disorders and reduced brain volume with 16p13.11 microduplication 56 . Investigating whether imbalances between pro-and anti-phagocytic signals, such as calreticulin and CD47, regulate brain size more generally in other conditions associated with brain overgrowth or undergrowth may lead to novel therapeutic strategies to prevent and treat these neurodevelopmental disorders.
Materials and Methods
Characterization and maintenance of hiPSCs
Induced pluripotent stem cell (iPSC) lines used in this study are listed in Supplementary Table 1 and obtained from the Simons Foundation Autism Research Initiative (SFARI) database via Simons Variation in Individuals Project (VIP). Full phenotypic information and clinical information for each patient were provided by VIP. A total of eleven human iPSC lines were used in the study. Cells were cultured and maintained in mTeSR medium (Stem Cell) with 10 µM ROCK inhibitor (Y27632, Stemgent) at 37 o C and 5% CO2 on Matrigel (BD Biosciences). Prior to differentiation, all hiPSC lines were immunostained against OCT3/4 and NANOG for pluripotency analysis. We also verified that genes within the 16p11.2 locus of the iPSCs have altered gene expression corresponding to either the 16p11.2 deletion or duplication. Control lines have been confirmed to have no genetic abnormalities.
Regulatory and Institutional Review
All human pluripotent stem cell experiments were conducted in accord with experimental protocols approved by the Stanford Stem Cell Research Oversight (SCRO) committee.
Generation of neural progenitor cells (NPCs)
Control and 16p11.2 CNV iPSCs were differentiated into cortical neural progenitor cells (NPCs) as previously described 29, 30 . The iPSC cultures were plated at a high-density monolayer onto GelTrex (ThermoFisher) coated wells. When cells were confluent, neuroectoderm differentiation began in Essential 6 Media (ThermoFisher) supplemented with small chemical inhibitors of the TGF, SMAD, and Wnt pathways, 500 nM LDN193189 (Tocris) + 10 µm SB431542 (Tocris) + 2 µM of XAV939 (Tocris) for three-days and then 500 nM LDN193189 + 10 µm SB431542 for the remaining nine days of differentiation. Media was changed daily.
Directed differentiation of oligodendrocyte progenitor cells (OPCs)
Oligodendrocyte progenitor cells were differentiated from control and 16p11.2 CNV iPSC lines following published protocols 43 . In brief, iPSCs were plated at a density of 1 X 10 5 per well on Matrigel-coated sixwell plates containing mTeSR and 10 µM ROCK inhibitor. The differentiation medium containing DMEM/F-12 (Life Technologies), 10 μM SB431542 (Stemgent), 250 nM LDN193189 (Stemgent), 100 nM all-trans retinoic acid (RA, Sigma-Aldrich), 1 µM smoothened agonist (SAG, EMD Millipore) was applied for 12 days. Fresh media was changed daily. Subsequently, cells were detached using a Corning cell lifter (Sigma-Aldrich) and transferred to ultra-low-attachment plates for the formation of spheres. From day 12, the differentiation media was changed every other day. (Sigma-Aldrich), 100 ng/ml Biotin (Sigma-Aldrich), 1 µM N6,2′-O-Dibutyryladenosine 3′,5′-cyclic monophosphate sodium salt (cAMP; Sigma-Aldrich) and 60 ng/ml 3,3,5-Triiodo-l-thyronine (T3; Sigma-Aldrich). On day 30, aggregates were plated for attachment on poly-l-ornithine/laminin-coated plates. The oligodendrocytes were continued to be expanded and differentiated in the OPC induction medium until harvested. The cells were immunostained with oligodendroglial specific markers, such as Olig2, Nkx2.2, and O4, to confirm their progression into the oligodendrocyte lineage.
Immunocytochemistry
Cells were fixed in cold 4% paraformaldehyde in phosphate buffered saline (PBS; Santa Cruz Biotechnology) for 20 minutes to one hour under room temperature. Subsequently, the cells were rinsed three times in PBS. For the nuclear staining, cells were permeabilized with 0.3% Triton X-100 (Fisher Bioreagents) for 15 minutes and washed three times with PBS. Subsequently, blocking solution containing 5% normal donkey serum (Jackson ImmunoResearch) /0.3 % TrionX-100 in PBS was applied for one hour. The primary antibodies and corresponding dilutions used were: rabbit-anti-PAX6 (1:500; Biolegend); mouse-anti-Nestin (1:500; R&D Systems); rabbit-anti-Olig2 (1:100; EMD Millipore); mouseanti-Nkx2.2 (1:50; DSHB); goat-anti-Sox10 (1:500; R&D Systems); mouse-anti-Oct3/4 (1:500; SantaCruz Biotechnology) and rabbit-anti-NANOG (1:500; Stemgent). After overnight primary antibody incubation at 4 o C, cells were rinsed in PBS/0.3 % TrionX-100, incubated with fluorescently tagged secondary antibodies (Alexa-Fluor goat/donkey-anti-primary antibody species IgG 488 or 549; Life Technologies) for one hour. Nuclear dye, DAPI (4,6-diamidino-2-phenylindol, Life Technologies), was used to stain all cells. All images were acquired using a Leica Fluorescent Microscope.
The mouse-anti-O4 surface antigen (1:500; clone 81; EMD Millipore) was used to identify hiPSC-derived OPCs. After 15 minutes of fixation in cold 4% paraformaldehyde/PBS, the cells were blocked in 1% BSA (Sigma-Aldrich) /5% normal donkey/ PBS for one hour at room temperature, and subsequently immunolabeled as described above. The images were taken by confocal microscopy.
RNA isolation and quantitative real-time PCR
Total RNA was isolated from control and 16p11.2 CNV hiPSCs, and hiPSC-derived NPCs and OPCs using the RNeasy Mini Kit (QIAGEN) following manufacturer's instructions. RNA was quantified using the NanoDrop spectrophotometer. Reverse transcription was performed subsequently to synthesize cDNA using SuperScript IV VILO Master Mix with ezDNase (Thermo Fisher) using the same quantity of RNA for all samples.
Quantitative Real-Time PCR (qRT-PCR) was performed using the SYBR green system. One reaction included SYBR green mix (Applied Biosystems), the forward and reverse target gene primers, and 100-120 ng cDNA. The StepOnePlus Real-Time PCR System (AppliedBiosystems) was used to run the qRT-PCR experiment. The expression of RNA transcripts was analyzed using the ΔΔCT method. Three biological, as well as three technical replicates, were conducted. All samples were normalized to the expression of the housekeeping gene gapdh. Primer sequences used in this study are listed in Supplementary Table 2 .
Confocal microscopy
O4 staining in OPCs derived from control and 16p11.2 CNV iPSC lines, and the mouse brain tissue sections stained with the monoclonal Human Cytoplasmic Marker (STEM121) and microglial/macrophage marker (Iba1) were imaged using Zeiss LSM710 Confocal Microscope with excitation laser lines at 405 (DAPI), 488 (GFP) and 594 nm using a 40X plan-fluor oil-immersion objective.
Flow Cytometry Analysis
The iPSCs, NPCs, or OPCs were dissociated using Accutase (Life Technologies). The target cells were subsequently suspended in FACS buffer containing 2% bovine serum albumin (BSA; Sigma), and 2 mM EDTA in PBS. Cells were then stained with following antibodies for 30 minutes on ice: Anti-human-NG2 Chondroitin Sulfate Proteoglycan, Cy3 (1:100; Millipore); Anti-human-CD47-APC (Clone: B6H12; 1:100; ThermoFisher); anti-human-Calreticulin-PE (1:100; Enzo Life Sciences); anti-mouse/human-CD11b-FITC (Clone: M1/70; 1:100; Biolegend); anti-human-CD45-PE (Clone: 2D1; 1:100; Biolegend); and anti-mouse-CD45-PE (Clone: 30-F11; 1:100; Biolegend). The lectin fluorescein labeled Phaseolus Vulgaris Leucoagglutinin (PHA-L) (1:200; Vector Laboratories) was used to stain for PHA-L. For O4 staining, the cells were first incubated in primary antibody mouse-anti-O4 antibody (Clone 81; 1:100; EMD millipore), followed by secondary antibody incubation, anti-Mouse IgM Alexa Fluor 488 (1:1000; Life Technologies). The cells were then washed twice with FACS buffer. DAPI (Sigma) was used to exclude dead cells. Immediately prior to flow cytometric analysis, the cells were strained through a 100 µM filter. Flow cytometry analyses were performed on the BD FACS Aria II (Becton Dickinson) and data were analyzed using FlowJo software (FloJo LLC). CD47 expression was measured using mean fluorescence intensity (MFI). The MFI of cell surface calreticulin (CRT) expression was obtained from the CD47+ population. Representative unstained controls for CD47 and cell surface CRT MFI are shown in Supplementary Figure 7 . The MFI for PHA-L expression was also measured.
O4-positive cell sorting
To obtain a pure population of O4-expressing OPCs, the mouse-anti-human-O4 antibody (Clone 81; 1:100; EMD millipore) was used to stain the 50 day-hiPSC derived-OPCs. The cells were incubated in the primary antibody for 40 minutes on ice, washed with FACS buffer, and subsequently stained with Alexa Fluor 488 goat anti-mouse IgM (μ-chain; Life Technologies) for 30 minutes on ice. The cells were rinsed twice with FACS buffer. DAPI stain was used to exclude dead cells. Immediately prior to flow cytometric analysis, the cells were strained through a 100 µM filter.
O4-positive cell sorting were performed on the BD FACS Aria II (Becton Dickinson) using Accudrop experiments. Cells were sorted into a clean FACS tube containing Buffer RLT (RNeasy Mini Kit, QIAGEN) for RNA extractions as described above. For each cell line, 1 X 10 4 cells were collected.
In vitro phagocytosis and anti-CD47 treatment
To generate human peripheral blood-derived macrophages, CD14+ monocytes were enriched from human peripheral blood (purchased from Stanford Blood Center) and cultured in Iscove's Modified Dulbecco's Medium (IMDM; ThermoFisher) with 10% human serum to differentiate to macrophages. After 7 days differentiation, human macrophages are ready for the phagocytosis. The hiPSCs and hiPSCderived NPCs (at 12 days differentiation) and OPCs (at 50 days differentiation) were fluorescently labeled with CellTrace (far red; ThermoFisher). The human macrophages were lifted using TrypLE (Gibco) and Corning cell lifter, and transferred to 10% human serum/DMEM. In a 3:1 ratio of macrophages (approx. 7.5 X 10 4 cells) to target cells (approx. 2.5 X 10 4 cells), the cells were mixed in sterile polystyrene tubes (Fisher Scientific), and incubated at 37 o C for 2 hours on a shaker (250 rpm) to promote macrophage and target cell interaction. Subsequently, the cells were washed in cold FACS buffer (2 mM EDTA/2% BSA/PBS) and stained for human marker Human-CD45-PE (Clone: 2D1; 1:100; Biolegend) before analysis on the FACS Aria II machine. 7-AAD (Biolegend) stain was used to exclude dead cells.
Treatment with the CD47 blocking antibody was performed immediately after CellTrace labeling. The InVivoMAb anti-human CD47 antibody (Clone: B6.H12; BioXcell) was diluted to 10 µg/ml in DMEM and applied to the target cells for 30 minutes on ice. Samples were then washed in 10%FBS/DMEM and processed for co-incubation with human macrophages as described above.
Mice Maintenance
The NOD scid gamma mice (NSG mice) were kept at a high barrier conditions and under pathogen-free environment in Lokey Stem Cell Building at Stanford University. All animal handling, surveillance, and experimentation were performed in accordance with approval from the Stanford University Administrative Panel on Laboratory Animal Care.
In vivo phagocytosis and anti-CD47 treatment
The target cells were detached using Accutase, counted, stained following manufacturer's recommendation with CellTrace (far red; ThermoFisher), and stored on ice until injection. Each P2-6 NOD-scid IL2gammanull (NSG) mouse was anesthetized by hypothermia and received a bilateral injection of 1L (0.5L DMEM/F12 and 0.5L HBSS) containing 30,000 cells of either NPCs or OPCs using a 10L Hamilton microsyringe (Hamilton Company). The injection site was determined by injecting at midline, +1mm rostral of lambda and injection took place through the skin and soft skull. The pups were gently warmed and then returned back to their mother when active. Twenty-four hours post-injection, pups were euthanized by decapitation under hypothermia and the fresh brains removed and placed in cold HBSS media on ice as previously described 57 . 2mm x 2mm cortical piece of tissue from the midline injection site was subject to neural dissociation (Neural Tissue Dissociation Kit; Miltenyi Biotec). Following dissociation, the cells were strained through a 100m filter and suspended in FACS buffer. All cells were then stained using Mouse/Human-CD11b-FITC (Clone: M1/70; 1:100; Biolegend); Mouse-CD45-PE (Clone: 2D1; 1:100; Biolegend). Dead cells were excluded using DAPI, and samples were analyzed on FACS Aria II machine. The targeted NPCs and OPCs population could be determined by APCpositive gating. The relative ratio of phagocytosed target cells was determined by co-expression of CD11b-FITC-and CD45-PE-positive cells.
Treatment with the CD47 blocking antibody was performed immediately after cell injection. 1µl of 250µg/mL of CD47 blocking antibody (Hu5F9-G4, acquired from Forty Seven) was injected intraperitoneally into the pups. The pups were gently warmed and then returned back to their mother when active. Twenty-four hours post-injections, brains were processed, stained, and analyzed by flow cytometry as described above.
Serial Sectioning and Staining
For histological evaluations, brains were extracted and placed in 4% Paraformaldehyde (PFA; Electron Microscopy Science) for 24 hours at 4 o C. Brains were then placed in 30% sucrose solution (Sigma) dissolved in deionized water for 48 hours and/or until brains sank to the bottom. They were then embedded in optimal cutting temperature compound (OCT; Fisher Scientific). Serial coronal sections were cut at 20 µm thick using a Cryostat at 200µm apart for a total of 5 sections per animal spanning the injection site and then stored at -80 o C. At room temperature (RT), the dried sections were postfixed with 10% formalin, washed 3 times in 1x PBS, and blocked in 2% donkey serum with 0.1% Triton X-100 for 1 h. Slides were then incubated with primary antibody diluted in blocking solution at 4 o C overnight: mouse-monoclonal Human STEM121 (1:500; Takara) for detecting human cytoplasmic protein and Rabbit-anti-Iba1 (1:500; Wako) for identifying mouse microglia and infiltrating macrophages. Sections were washed 5 times with 1 X PBS and incubated with fluorescently tagged secondary antibodies (Alexa-Fluor mouse IgG 488 or rabbit 594; Life Technologies) for one hour at RT. Following staining, the slides were then washed 3 X in 1 X PBS and then mounted in Pro-long anti-fade mounting solutions with DAPI.
Statistical analysis
All data are graphed as bar blots using the ggplot2 library in RStudio Desktop 1.1.463 environment (https://www.statmethods.net/advgraphs/ggplot2.html). Mean values with standard errors of the mean (SEM) are reported. Student's unpaired two-tailed t test was used for comparisons of two experimental groups. Multiple comparisons were analyzed using one-way analysis of variance (ANOVA) followed by post-hoc Tukey HSD Test. P value ≤ 0.05 was considered statistically significant. When p values are not reported in the figures, there was no statistical significance. 
Figure Legends
